89 results on '"Poggio, F"'
Search Results
2. 108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)
3. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
4. P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial
5. 69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial
6. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
7. 307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer
8. 118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella
9. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
10. Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’
11. 226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study
12. 1740P Assessing the impact of COVID-19 outbreak on the attitudes and practice of Italian oncologists towards breast cancer care and related research activities
13. 1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a national survey
14. 95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)
15. 148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)
16. Bulk Explosive Detection by Neutron Interrogation: Results from the Explodet Collaboration.
17. Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial
18. Dose-dense adjuvant chemotherapy in early breast cancer: 15–year results of the phase III Mammella InterGruppo (MIG)-1 study
19. The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial
20. USE OF ZEEMAN GFAAS IN THE ANALYSIS OF TRACE ELEMENTS IN DIALYSIS FLUIDS
21. DETERMINATION OF TRACE ELEMENTS IN BONE BY GFAAS WITH ZEEMAN CORRECTION
22. Efficacy and Tolerability of Cilazapril (CLZ) in Hypertensive Patients (PTS) with Chronic Renal Failure (CRF)
23. Free Erythrocyte Protoporphyrin in Hemodialysis Patients Treated with Human Recombinant Erythropoietin
24. Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab
25. Should anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized controlled trials (RCTs)
26. Physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey
27. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
28. The BCY3/BCC 2017 survey on physicians’ knowledge, attitudes and practice towards fertility and pregnancy issues in young breast cancer patients
29. Abstract GS4-01: Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients
30. A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer
31. Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study
32. The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)
33. The pregnancy and fertility (PREFER) study: A prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)
34. Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis
35. The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: an international multicentre hospital-based retrospective cohort study
36. Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study
37. An international multicentre hospital-based retrospective cohort study evaluating the prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients
38. TP53 germline mutation testing in early onset breast cancer
39. Concurrent versus sequential adjuvant chemo-endocrine therapy in early stage hormone receptor-positive breast cancer patients: a systematic review and meta-analysis
40. Dose-dence adjuvant chemotherapy in early breast cancer: the results of 15 years of follow-up
41. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies
42. Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: a systematic review and meta-analysis of randomized studies
43. Does body mass index impact on clinical outcomes in her-2 positive metastatic breast cancer?
44. Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients
45. Correlation between treatment with aromatase inhibitors and carotid intima-media thickness, carotid stenosis and abdominal aortic diameter. A prospective cohort study
46. Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (PREgnancy and FERtility) trial
47. The value of hormone serum concentration to predict the gonadotoxic effect of chemotherapy and the efficacy of LHRH analogs as a strategy to reduce treatment-related premature ovarian failure in breast cancer
48. Outcomes of hormone-responsive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC) patients (P) according to their starting first-line (1st) treatment (T): chemotherapy (CT) or hormonal therapy (HT)
49. First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (NEO)adjuvant trastuzumab
50. 1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.